1091TiP STARBOARD: Randomized phase III study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma

Authors :: A. di Pietro
Antoni Ribas
Reinhard Dummer
Anna Polli
Dirk Schadendorf
T. Panella
Meredith McKean
K. Brill
P.A. Ascierto
C. Robert
Ryan J. Sullivan
Edgardo S. Santos
Source :: Annals of Oncology. 32:S902
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: business.industry
Melanoma
Mutant
Locally advanced
Binimetinib
Hematology
Pembrolizumab
medicine.disease
First line treatment
chemistry.chemical_compound
Oncology
chemistry
Encorafenib
Cancer research
Medicine
business

Tools